Correlation Between First Wave and SAB Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both First Wave and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining First Wave and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between First Wave BioPharma and SAB Biotherapeutics, you can compare the effects of market volatilities on First Wave and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in First Wave with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of First Wave and SAB Biotherapeutics.

Diversification Opportunities for First Wave and SAB Biotherapeutics

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between First and SAB is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding First Wave BioPharma and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and First Wave is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on First Wave BioPharma are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of First Wave i.e., First Wave and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between First Wave and SAB Biotherapeutics

If you would invest  269.00  in SAB Biotherapeutics on August 25, 2024 and sell it today you would earn a total of  44.00  from holding SAB Biotherapeutics or generate 16.36% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy4.55%
ValuesDaily Returns

First Wave BioPharma  vs.  SAB Biotherapeutics

 Performance 
       Timeline  
First Wave BioPharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days First Wave BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, First Wave is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.
SAB Biotherapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, SAB Biotherapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

First Wave and SAB Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with First Wave and SAB Biotherapeutics

The main advantage of trading using opposite First Wave and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if First Wave position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.
The idea behind First Wave BioPharma and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
CEOs Directory
Screen CEOs from public companies around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance